A Phase 2 interventional study of Glofitamab and Tocilizumab in Lymphoma, sponsored by Hoffmann-La Roche. Active, not recruiting at 20 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-30.
Sponsored by Hoffmann-La Roche · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies in Lymphoma by Hoffmann-La Roche — 1 open to participants now, 3 under way, 1 of them phase 3. Lymphoma · Hoffmann-La Roche.
Among the 17 studies in Lymphoma by Hoffmann-La Roche, this one is the 11th largest by enrollment of the 15 interventional ones that give a count, is the only one that started in 2022, is one of 3 in phase 2, and was the 15th registered.
3,018 studies on the registry are indexed under Lymphoma; 433 are open to participants now.
Browse Lymphoma studies →1 of the 17 studies in Lymphoma by Hoffmann-La Roche is open now, in 12 countries. Recruiting first, the newest first:
Hoffmann-La Roche · Sites in United States, Australia, Brazil and 10 more countries
Ages 18+
By country, each count listing its studies:
Of the 346 Lymphoma studies recruiting now, 227 (66%) set no upper age limit and 78 (23%) stop at 75 or younger; 77 take children under 18; 20 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 7 · Phase 3 4
First in 2002; this study’s year is marked. 1 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 46 is close to the median of 43 across 2,319 interventional studies indexed under Lymphoma.
Median enrollment 96 across the 15 interventional studies, 421 across the 2 observational. Of the 14 that completed or were terminated, 8 (57%) have results posted.
This tab as a report to print or save as PDF → With an account.
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 331 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
2 of the studies in Lymphoma by Hoffmann-La Roche that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06084936Phase 3Hoffmann-La RocheA Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma | 2027-08-31 |
| NCT06624085Hoffmann-La RocheA Study Evaluating the Safety and Efficacy of Glofitamab + Gemcitabine + Oxaliplatin in U.S. Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma | 2027-03-22 |
Add all 2 to your calendar (.ics) → With an account.
Among the 17 studies in Lymphoma by Hoffmann-La Roche, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This Phase II, open-label, multicenter study will evaluate the safety, efficacy, and pharmacokinetics of glofitamab in combination with rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in individuals with circulating tumor DNA (ctDNA) high-risk diffuse large B-cell lymphoma (DLBCL), as the first line of treatment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Previously untreated patients with CD20-positive DLBCL, including one of the following diagnoses made according to the 2016 World Health Organization (WHO) classification of lymphoid neoplasms
Additional Inclusion Criterion for ctDNA High-Risk Participants:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive step-up doses of glofitamab, starting on Day 8 of Cycle 3 (2.5 mg), Day 15 of Cycle 3 (10 mg), then 30 mg glofitamab will be given every three weeks (Q3W) onwards, on Day 8 of Cycles 4-6 and on Day 1 of Cycles 7-10. (cycle length = 21 days) Participants will receive rituximab, cyclophosphamide, doxorubicin, and vincristine Q3W on Day 1 of Cycles 1-6. Prednisone or prednisolone will be administered daily (QD) on Days 1-5 of Cycles 1-6. (cycle length = 21 days)
Drug: Glofitamab · Drug: Tocilizumab · Drug: Doxorubicin · Drug: Vincristine · Drug: Prednisone · Drug: Rituximab · Drug: Cyclophosphamide
Participants will receive intravenous (IV) glofitamab as per schedule specified in the treatment arm.
Participants will receive tocilizumab as needed to manage cytokine release syndrome (CRS).
Participants will receive 50 mg/m2 body surface area of doxorubicin IV as per schedule specified in the treatment arm.
Participants will receive 1.4 mg/m2 body surface area of vincristine IV as per schedule specified in the treatment arm.
Participants will receive 100 mg of prednisone or prednisolone as per schedule specified in the treatment arm.
Participants will receive 375 mg/m2 body surface area of rituximab IV as per schedule specified in the treatment arm.
Participants will receive 750 mg/m2 body surface area of cyclophosphamide IV as per schedule specified in the treatment arm.
End of Treatment Complete Response (EOT CR) Rate
Time frame: Up to approximately 24 months
Overall Response Rate (ORR) at the EOT
Time frame: Up to approximately 24 months
Progression-free Survival (PFS)
Time frame: Up to approximately 24 months
Overall Survival (OS)
Time frame: Up to approximately 24 months
Percentage of Participants With Adverse Events (AEs)
Time frame: Up to 90 days after the final dose of study treatment
Serum Concentration of Glofitamab
Time frame: At pre-defined intervals up to approximately 10 months
Maximum Concentration (Cmax) of Glofitamab
Time frame: At pre-defined intervals up to approximately 10 months
Total Exposure (AUC) of Glofitamab
Time frame: At pre-defined intervals up to approximately 10 months
| Milestone | Glofitamab + R-CHOP Immunochemotherapy |
|---|---|
| Started | 45 |
| Completed | 0 |
| Not completed | 45 |
| Withdrew: Study ongoing | 41 |
| Withdrew: Death | 1 |
| Withdrew: Withdrawal by subject | 3 |
| Percentage of participants | Glofitamab + R-CHOP Immunochemotherapy |
|---|---|
| End of Treatment Complete Response (EOT CR) Rate | 73.3 (58.06 to 85.40) |
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Collected over Approximately 43 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Glofitamab + R-CHOP Immunochemotherapy | 1/45 (2.2%) | 20/45 (44.4%) | 40/45 (88.9%) |
| Event | Glofitamab + R-CHOP Immunochemotherapy |
|---|---|
| Cytokine release syndromeImmune system disorders | 9/45 |
| NeutropeniaBlood and lymphatic system disorders | 3/45 |
| AnaemiaBlood and lymphatic system disorders | 1/45 |
| Febrile neutropeniaBlood and lymphatic system disorders | 1/45 |
| ThrombocytopeniaBlood and lymphatic system disorders | 1/45 |
| Sinus tachycardiaCardiac disorders | 1/45 |
| Jejunal perforationGastrointestinal disorders | 1/45 |
| Large intestinal obstructionGastrointestinal disorders | 1/45 |
| PyrexiaGeneral disorders | 1/45 |
| InfectionInfections and infestations | 1/45 |
| Event | Glofitamab + R-CHOP Immunochemotherapy |
|---|---|
| NeutropeniaBlood and lymphatic system disorders | 16/45 |
| DiarrhoeaGastrointestinal disorders | 11/45 |
| Platelet count decreasedInvestigations | 10/45 |
| AnaemiaBlood and lymphatic system disorders | 9/45 |
| Neutrophil count decreasedInvestigations | 9/45 |
| COVID-19Infections and infestations | 8/45 |
| ThrombocytopeniaBlood and lymphatic system disorders | 6/45 |
| FatigueGeneral disorders | 6/45 |
| PyrexiaGeneral disorders | 6/45 |
| Neuropathy peripheralNervous system disorders | 6/45 |
| Age, Continuous(Years) | Glofitamab + R-CHOP Immunochemotherapy |
|---|---|
| Median | 64.0 (39 to 79) |
| Sex: Female, Male(Participants) | Glofitamab + R-CHOP Immunochemotherapy |
|---|---|
| Female | 15 |
| Male | 30 |
| Ethnicity (NIH/OMB)(Participants) | Glofitamab + R-CHOP Immunochemotherapy |
|---|---|
| Hispanic or Latino | 4 |
| Not Hispanic or Latino | 29 |
| Unknown or Not Reported | 12 |
| Race (NIH/OMB)(Participants) | Glofitamab + R-CHOP Immunochemotherapy |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 2 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 1 |
| White | 32 |
| More than one race | 0 |
| Unknown or Not Reported | 10 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing
Ran from Mar 2022 to primary completion in Oct 2024, 31 months.
Results were first posted in Aug 2026, 1 year 9 months after primary completion.
Of 56 industry-sponsored phase 2 interventional studies under Lymphoma, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 65. This study's 31 months is below that.
Counting every sponsor, half of 293 studies reached it within 61 months; a quarter within 36 and three quarters within 105.
Since we started tracking on Sep 25, 2026, the dates moved once, on Sep 30, 2026: primary completion Sep 2024 → Oct 2024 and completion Sep 2026 → Oct 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Glofitamab